A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)

NCT06113471 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

450

Enrollment

INDUSTRY

Sponsor class

Conditions

NonSegmental Vitiligo

Interventions

DRUG: Povorcitinib
DRUG: Placebo

Sponsor

Incyte Corporation